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Eosinophilia in Patients 
Infected with the Human 
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A. Tietz 1, L. Sponagel 1, E Erb e , 
H. Bucher 1, M. Battegay 1, W. Zimmerli 3. 
The prevalence and significance of peripheral 
blood eosinophilia in patients infected with the hu- 
man immunodeficiency virus (HIV) were evaluated. 
Fifteen of 119 consecutive patients had absolute 
eosinophil counts of > 450/ram 3. During a mean fol- 
low-up period of 419 days eosinophilia could be 
identified as secondary to a parasitic infection in 
only one patient. Correlation with disease stage 
showed a higher rate of advanced disease in pa- 
tients with absolute eosinophilia. In a multivariate 
regression analysis, only low CD4+ cell counts, not 
the CDC disease stage or the use of antiretroviral 
therapy or primary prophylaxis, contributed signif- 
icantly to the prevalence of eosinophilia. It is con- 
cluded that expen-sive laboratory investigations in 
asymptomatic patients with advanced-stage HIV 
disease are neither necessary nor cost effective. 
The occurrence of peripheral blood eosinophilia 
in patients with human immunodeficiency type 1 
(HIV-1) infection has been described previously 
(1-4). Our daily clinical work suggested that 
eosinophilia is more common in late-stage infec- 
tion. Previous retrospective studies have shown ei- 
ther no significant difference in its incidence as re- 
lated to various disease stages (1, 2) or a strong as- 
sociation with advanced isease (3, 5). 
The major hypotheses for an increased prevalence 
of peripheral blood eosinophilia in advanced 
HIV-1 infection include the Thl-Th2 shift of 
HIV-infected CD4+ lymphocytes, associated with 
higher levels of interleukin-4 and -5 and a subse- 
quent increase in immunogtobulin E (IgE) levels 
(5-8); parasitic disease not detectable by routine 
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laboratory methods (4); the infection of CD4+ 
receptor-positive osinophils by HIV (since 
eosinophils are able to produce their own growth 
factor) (9, 10); and the numeric decline of other 
blood cell lines, leading to a reactive proliferation 
of eosinophils (11). The aim of this study was to 
evaluate the prevalence, possible etiolog3; and 
correlation with demographic and biologic vari- 
ables of eosinophilia in HIV-infected patients. 
Materials and Methods. We performed a retro- 
spective analysis of charts from 119 Caucasian 
HIV-l-positive patients who were monitored in a 
prospective cohort study (the Swiss HIV Cohort 
Study) at our center. Semiannual follow-up visits 
included a history and physical examination, 
complete blood cell counts, lymphocyte differen- 
tiation, chemograms, serologic assays, and, if nec- 
essary additional diagnostic tests. 
Peripheral blood eosinophilia was defined as an 
absolute osinophil count of > 450/mm 3 on at least 
two subsequent measurements. No specific rou- 
tine program for the investigation of eosinophil- 
ia is used at our clinic, but all evaluations includ- 
ed analysis of multiple stool samples and serolog- 
ic tests for common HIV-associated parasites as 
well as skin biopsies in a few cases with concur- 
rent dermatosis. Basic features of the patients with 
eosinophilia were identified and compared to 
those of the control subjects. The 15 case subjects 
were then paired in a 1:1 fashion with an HIV- 
positive control group matched for age, sex, 
transmission mode, and stage of disease. Levels 
of interleukin-4, interleukiu-5, interferon-s, and 
IgE were measured in serum samples of both 
groups with modified enzyme-linked assays 
(12, 14). Serum samples for determination of cy- 
tokine profiles and IgE levels were collected at the 
time of detection of eosinophilia. 
Results underwent univariate and multivariate 
regression analysis (p < 0.05) with a statistical soft- 
ware program (SPSS for Windows, Version 6.0; 
SPSS, USA). 
Results and Discussion. Of 119 subjects evaluat- 
ed 15 (12.6%) had absolute osinophilia (range, 
451-2940/~tl; median, 720/~1). Intergroup compar- 
ison showed a significantly higher proportion of 
patients with low CD4+ cells and CDC disease 
stage C in the group with eosinophilia. Table 1 
summarizes the characteristics of both groups. 
Patients with eosinophilia were significantly old- 
er, and a higher proportion was using antiretrovi- 
ral medication, which is consistent with the in- 
creased prevalence of advanced-stage disease in 
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Table 1: Characteristics of HIV-positive patients with and without eosinophilia. 
Characteristic Patients with eosinophilia Patients without eosinophilia P value 
(n = 15) (n = 104) 
Mean age (years) 45.9 
Male 13 (86.7%) 
Mean duration of HIV seropositivity (years) 6.4 
History of asthma 0 
History of allergy/atopy 4 (19,1%) 
Eczema 8 (38.1%) 
Folliculitis 6 (28.6%) 
Tissue eosinophilia 1 (4.8%) 
Intestinal parasites in stool samples 1 (4.8%) 
CDC disease stage b 
A 1 (6.7%) 
B 5 (33.3%) 
C 9 (60.2%) 
CD4+ cell count 
> 500/~JI 1 (6.6%) 
200-500/IJI 2 (13.3%) 
< 200/IJI 12 (80.0%) 
Transmission mode 
Homosexual 8 (53.3%) 
Intravenous drug abuse 3 (20.0%) 
Heterosexual 3 (20.0%) 
Blood products 1 (6.7%) 
Antiretroviral therapy d 11 (73.3%) 
Primary PCP prophylaxis e 8 (53.3%) 
36.3 0.015 a 
75 (72.1%) ns 
6.3 ns 
2 (1.9%) ns 
17 (16.3%) ns 
23 (22.1%) ns 
16 (15.3%) ns 
0 ns 
4 (3.8%) ns 
28 (26.9%) 
52 (50.0%) 
24 (23.1% < 0.005 c 
10 (9.6%) 
45 (43.3%) 
49 (47.1%) 0.017 c 
39 (37,5%) ns 
46 (44.2%) ns 
19 (18.3 %) ns 
0 ns 
44 (36.9%) 0.025 c 
39 (37.5%) ns 
a Levene's t-test for equality of variances. 
b CDC disease stage definition: A, asymptomatic; B, minor opportunistic diseases; C, acquired immunodeficiency syndrome; 
c ManteI-Haenszel test for linear association. 
d Antiretroviral drugs used were zidovudine, didanosine, and zalcitabine. 
e Cotrimoxazole or dapsone/pyrimethamine. 
ns, not significant; PCR Pneumocystis carinii pneumonia. 
this group. The results of the multivariate logistic 
regression analysis indicate that a CD4+ cell 
count below 200/jal is significantly associated with 
an increased risk for peripheral blood eosinophil- 
ia (Table 2). The use of antiretroviral therapy 
(reverse transcriptase inhibitors: zidovudine, 
didanosine, or zalcitabine) did not contribute to 
the model significantly, in contrast to the findings 
from the univariate analysis. The duration of 
seropositivity was similar in both groups, indicat- 
ing coincidence between rapid progression and 
eosinophilia. 
On retrospective valuation, one patient had 
severe eczema and erythrodermia with tissue 
eosinophilia. He also had a history of travel in the 
Table 2: Multivariate anaJysis of variables associated with peripheral blood eosinophilia in HtV-positive patients (Cox 
proportional hazards model). 
Variable Adjusted risk ratio 95% Cl P value 
CD4+ cell count < 200/IJI 2.81 1.09-7.24 0.03 
Disease stage C 1.82 0.95-3.51 0.07 
Antiretroviral therapy a 0.62 0.29-1.34 ns 
Primary PCP prophylaxis b 2.09 0.98-4.89 0.09 
a Zidovudine, didanosine, or zalcitabine. 
b Cotrimoxazole or dapsone/pyrimethamine. 
ns, not significant; PCP, Pneumocystis carinii pneumonia. 
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tropics and transient Trichuris trichiura infection 
detected by stool examination. During a median 
follow-up time of 419 days (range, 89-1769 days), 
we detected no other cases of secondary 
eosinophilia. Therefore, we propose that in the ab- 
sence of epidemiologic, anamnestic, or clinical 
symptoms indicating parasitic disease, allergic 
disorders, neoplasms, or skin disease, three stool 
samples for bacteria, ova, and parasites are suffi- 
cient for evaluation. In view of our findings, a com- 
plete series of tests including chest radiographs, ab- 
dominal ultrasound, serologic evaluation for par- 
asitic disease, or even bone marrow aspiration is 
unnecessary. 
Interleukin-4, interleukin-5, and interferon-~ lev- 
els were undetectable in both groups, i.e., subjects 
with eosinophilia nd the matched control sub- 
jects. There was no statistically significant differ- 
ence between the groups in immunoglobulin E 
levels (20.6 + 12.9 ng/ml in eosinophilic patients 
vs. 13.0 _+ 7.5 ng/ml in patients without eosinophil- 
ia; p = 0.32 with the two-tailed Student's t-test). 
As to the possible reasons for the higher rate of 
eosinophilia in patients with late-stage disease, our 
data were not able to reproduce any cytokine mod- 
ulations attributed to the Thl-Th2 shift hy- 
pothesis. This finding may be due to our use of se- 
rum instead of supernatants ofT cells for our ana- 
lyses. Patients with eosinophilia had IgE levels 
similar to those found in the control subjects 
which precludes us from interpreting eosinophil- 
ia in HIV infection as indicative of an allergic re- 
action. Nevertheless, ince severely immunocom- 
promised patients are more likely to receive 
multidrug regimens for the treatment of HIV 
infection and diseases associated with it, eosino- 
philia could denote a reaction to multiple-drug 
therapy. 
In conclusion, the prevalence of eosinophilia in pa- 
tients with HIV-1 infection was 12.6%; more than 
two-thirds of these patients were severely immu- 
nocompromised. There was no significant eleva- 
tion of serum IgE levels, suggesting a nonallergic 
cause. Our results indicate that eosinophilia is 
most probably associated with HIV infection 
when epidemiological or clinical features indica- 
tive of other conditions with eosinophilia are 
absent. 
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